logo-loader
Imugene Ltd

Imugene gets development roadmap for cancer vaccine from FDA meeting

The company had a pre-investigational new drug (IND) meeting with the FDA last month.

man in lab coat holding up test tube
The company met with 7 people from the US Food and Drug Administration (FDA)

Imugene Ltd (ASX:IMU) has received minutes of its meeting with the (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.

The meeting was aimed at seeking guidance on the studies required for phase I clinical development of KEY-Vaxx.

Topics addressed included the anticipated clinical indication and the treatment of cancers that overexpress PD-L1 including but not limited to non-small cell lung cancer.

Imugene’s managing director and CEO Leslie Chong said: “The meeting was productive and provided Imugene with a clear roadmap for a successful IND submission and subsequent clinical development of KEY-Vaxx.

“The FDA panel members encouraged Imugene to pursue the planned IND submission and subsequent clinical studies.”

READ: Imugene doses milestone first patient for cancer vaccine trial

Imugene is developing cancer immunotherapies targeting B-cell peptide vaccines.

Its most advanced drug being developed is HER-Vaxx cancer vaccine.

Last week Imugene dosed its first patient in its phase II study with its HER-Vaxx cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

Quick facts: Imugene Ltd

Price: $0.02

Market: ASX
Market Cap: $83.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the...

on 8/7/19

2 min read